Literature DB >> 29396810

The Prevalence of Extranodal Extension in Papillary Thyroid Cancer Based on the Size of the Metastatic Node: Adverse Histologic Features Are Not Limited to Larger Lymph Nodes.

Meghan E Rowe1, Umut Ozbek2, Rosalie A Machado1, Lauren E Yue3, Juan C Hernandez-Prera4, Alessandro Valentino5, Muhammad Qazi5, Margaret Brandwein-Weber5, Xulei Liu5, Bruce M Wenig4, Mark L Urken1,6.   

Abstract

Extranodal extension (ENE) is a prognostic indicator of aggressiveness for papillary thyroid cancer (PTC). The association between the size of metastatic nodes and the prevalence of ENE has not been previously explored. However, there is a common belief that small lymph nodes with metastatic disease do not significantly impact patient outcome. This study investigates the relationship between the prevalence of ENE and the size of a positive lymph node. Linear dimensions and malignant histological characteristics of 979 metastatic lymph nodes from 152 thyroid cancer patients were retrospectively analyzed. Data was analyzed using chi-square tests and multilevel logistic regression modeling. ENE was present in 144 of 979 lymph nodes; the sizes of the involved lymph nodes ranged from 0.9 to 44 mm. ENE was identified in 7.8% of lymph nodes measuring ≤ 5 mm, 18.9% between 6 and 10 mm, 23.1% between 11 and 15 mm, 25.0% between 16 and 20 mm, and 14.0% between 21 and 25 mm in size. The association between node size and ENE status was significant (odds ratio (OR) = 1.07, confidence interval (CI) = [1.04, 1.11]). The size of the metastatic focus directly correlated with ENE (OR = 1.07, 95% CI = [1.07, 1.14], p value < 0.001). Increasing lymph node size increases the likelihood of ENE for metastatic PTC. Importantly, small positive lymph nodes can also harbor ENE to a significant extent. Further studies are required to determine the clinical and prognostic significance of lymph node size and the presence of ENE.

Entities:  

Keywords:  Extranodal extension; Lymph node metastases; Lymph node size; Papillary thyroid carcinoma; Pathology; Size stratification

Mesh:

Year:  2018        PMID: 29396810     DOI: 10.1007/s12022-018-9518-7

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  4 in total

1.  Male patients with papillary thyroid cancer have a higher risk of extranodal extension.

Authors:  Hu Hei; Bin Zhou; Wenbo Gong; Chen Zheng; Jianwu Qin
Journal:  Int J Clin Oncol       Date:  2022-01-08       Impact factor: 3.402

2.  Macroscopic extranodal extension is an independent predictor of lung metastasis in papillary thyroid cancer.

Authors:  Hu Hei; Wenbo Gong; Chen Zheng; Bin Zhou; Jianwu Qin
Journal:  Endocrine       Date:  2022-04-07       Impact factor: 3.925

3.  The impact of thyroid tumor features on lymph node metastasis in papillary thyroid carcinoma patients in head and neck department at KAMC: A retrospective cross-sectional study.

Authors:  Amjad O Aljohani; Reyan H Merdad; Anas I Alserif; Layan S Alhemayed; Noor Z Farsi; Thamer A Alsufyani; Haddad H Alkaf; Ameen Z Alherabi; Sherif K Abdelmonim; Mohammad A Alessa
Journal:  Ann Med Surg (Lond)       Date:  2021-03-22

4.  Extranodal Extension Is an Independent Prognostic Factor in Papillary Thyroid Cancer: A Propensity Score Matching Analysis.

Authors:  Tian-Han Zhou; Bei Lin; Fan Wu; Kai-Ning Lu; Lin-Lin Mao; Ling-Qian Zhao; Ke-Cheng Jiang; Yu Zhang; Wei-Jun Zheng; Ding-Cun Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-03       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.